Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 310

1.

Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.

Xiao Z, Ding N, Xiao G, Wang S, Wu Y, Tang L.

Anat Rec (Hoboken). 2012 Dec;295(12):2122-8. doi: 10.1002/ar.22552. Epub 2012 Aug 21.

2.

Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.

Chen T, Wang C, Liu Q, Meng Q, Sun H, Huo X, Sun P, Peng J, Liu Z, Yang X, Liu K.

Cancer Biol Ther. 2015;16(1):106-14. doi: 10.4161/15384047.2014.987062.

3.
4.

Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.

Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T, Chayama K.

Int J Oncol. 2008 Dec;33(6):1187-94.

PMID:
19020751
5.

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function.

Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, Fu LW.

Cancer Chemother Pharmacol. 2009 Oct;64(5):961-9. doi: 10.1007/s00280-009-0949-1. Epub 2009 Mar 3.

PMID:
19255759
6.

Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.

Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.

World J Gastroenterol. 2012 Nov 21;18(43):6226-34. doi: 10.3748/wjg.v18.i43.6226.

7.

Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.

Ma SL, Hu YP, Wang F, Huang ZC, Chen YF, Wang XK, Fu LW.

Mol Med. 2014 Sep 8;20:390-9. doi: 10.2119/molmed.2014.00059.

8.

Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line.

Dong Y, Shao S, Hu J, Yang P.

Oral Oncol. 2009 Nov;45(11):991-7. doi: 10.1016/j.oraloncology.2009.05.642. Epub 2009 Jul 23.

PMID:
19631573
9.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
10.

[Significance and reversal of MDR1/P-gp in pancreatic cancer chemotherapy].

Guo JC, Zhao YP, Liao Q, Zhu Y.

Zhonghua Wai Ke Za Zhi. 2007 Nov 1;45(21):1488-90. Chinese.

PMID:
18275717
11.

Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.

Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.

Cancer Chemother Pharmacol. 2006 Nov;58(5):577-84. Epub 2006 Mar 11.

PMID:
16532343
12.

Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.

Chen JR, Jia XH, Wang H, Yi YJ, Wang JY, Li YJ.

Int J Oncol. 2016 May;48(5):2063-70. doi: 10.3892/ijo.2016.3423. Epub 2016 Mar 7.

PMID:
26984633
13.

[The role of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance of hepatocellular carcinoma].

Zhu H, Chen XP, Luo SF, Guan J, Zhang WG, Zhang BX, Mao CP.

Zhonghua Wai Ke Za Zhi. 2007 Jul 1;45(13):917-20. Chinese.

PMID:
17953842
14.

Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.

Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.

Cancer Chemother Pharmacol. 2006 Nov;58(5):640-53. Epub 2006 Mar 17.

PMID:
16544145
15.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
16.

Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin.

Tada Y, Wada M, Migita T, Nagayama J, Hinoshita E, Mochida Y, Maehara Y, Tsuneyoshi M, Kuwano M, Naito S.

Int J Cancer. 2002 Apr 1;98(4):630-5.

17.

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.

Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K.

Exp Cell Res. 2014 Mar 10;322(1):168-77. doi: 10.1016/j.yexcr.2014.01.007. Epub 2014 Jan 15.

18.

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.

Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y.

Breast Cancer Res. 2001;3(4):253-63. Epub 2001 Apr 2.

19.
20.

RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.

Xu ZH, Hang JB, Hu JA, Gao BL.

Int J Clin Exp Pathol. 2013 Jul 15;6(8):1493-504. Print 2013.

Supplemental Content

Support Center